Table 2.

Clinical trials evaluating target drug in ASPS.

Year	Author	Phase and clinical number	Drug	Effect
2019	Judson I et al	II (NCT01337401)	Cediranib 30 mg qd Cediranib VS placebo group	median PFS: 10.1 VS 4.9 (P = .28)12-mo PFS: 38.7% VS 34.4%median OS: 27.8 Vs 47.3 (P = .48)12-mo OS: 90 3% VS 68.8%
2019	Cohen JW et al	II (NCT00942877)	Cediranib (AZD2171)	ORR 35% at 24 wks, DCR 84% at 24 wks
2019	Kim M et al	II (NCT02113826)	Pazopanib 800 mg qd	median PFS 5.5 mo, 6-month PFS 50%
2018	Chi Y et al	II (NCT01878448)	Anlotinib 12 mg, qd	median PFS 5.6 mo, PFS 12 wks was 77% median OS 12 mo
2018	Schöffski et al	II (EORTC 90101) (NCT01524926)	Crizotinib 250 mg	1-year OS was 97.4% and 75.0% for MET+ and MET- patients
2018	Stacchiotti et al	Retrospective study	Pazopanib	median PFS for 13.6 months
2017	Schuetze et al	II (NCT00464620)	Dasatinib	PFS rate at 6 mo with 62% for ASPS
2017	Jagodzinska-Mucha P et al	Retrospective study (15 patients with metastatic ASPS)	Sunitinib 37.5 mg qd	median PFS reached 19 mo, median OS for 56 mo
2016	Li T et al	Retrospective study (14 patients with unresectable or metastatic ASPS)	Sunitinib 37.5 mg qd	median PFS for 41.0 mo, median OS not reached
2016	Kuo DJ	Case report (2 patients with widespread metastases)	Pazopanib, sorafenib, cediranib and sunitinib	survived over 5 y
	Kuo DJ	(multiple target agents)	Sorafenib, cediranib, pazopanib, sunitinib, axitinib, cabozantinib	survived over 5 y
2012	Wagner AJ et al	phase II trial (NCT00557609)	Tivantinib (ARQ 197) ASPS (n = 27)	median PFS was 5.5 mo for ASPS
2011	Stacchiotti et al	9 metastatic ASPS patients	Sunitinib 37.5 mg qd	the median PFS reached 17 months